CRA INTERNATIONAL, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
CRA International reported Q2 revenue up 12.8% YoY, beating estimates. Stock rose 5.1% but market reaction was muted. Company expanded credit facilities to $400M. Analysts project $890.9M revenue by 2029, a 43% upside. Concerns include debt levels and earnings volatility.
Simply Wall St discusses CRA International (CRAI) after it refinanced and expanded its credit facility to US$400 million in Aug 2026. The article cites record Q2 revenue of US$210.82 million, net income of US$13.51 million, ongoing share repurchases, and a quarterly dividend of US$0.57 per share, and links the move to capital allocation and investment risk.
CRA International (CRAI) reported Q2 FY2026 revenue of $210.8 million, up 12.8%, and non-GAAP EPS of $2.16, up 14.9%. Non-GAAP EBITDA was $26.8 million. Management raised full-year 2026 revenue guidance to $805-$820 million and reaffirmed EBITDA margin of 12.0%-13.0%. The company repurchased shares and expanded its $400 million credit facility.
Over the past 7 days, alphai's AI scored 1 news story mentioning CRAI (CRA INTERNATIONAL, INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent CRAI coverage spans earnings, financial news and corporate actions.
In the last 30 days, CRAI insiders filed 5 SEC Form 4 transactions — no purchases and 5 sales ($391K). The most active reporter was Yellin Jonathan D, EVP AND GENERAL COUNSEL, with 3 filings. 60% of those filings were made under pre-arranged Rule 10b5-1 plans.
Strong earnings beat and new financing could support growth, but muted price reaction suggests limited immediate upside.
The $400M expanded facility modestly improves near-term liquidity and flexibility, but the article frames ongoing leverage and demand cyclicality as key risks.
Raised revenue guidance with margin targets intact, plus balance-sheet expansion and buybacks, suggests improving demand and cash generation visibility.
Guidance lift and broad practice growth are supportive, but margin pressure and working-capital cash use raise near-term execution risk.
Guidance upside supports the valuation, but margin compression and net debt from working-capital use raise near-term risk.
alphai scores every news story that mentions CRAI with an AI model for sentiment and relevance, and aggregates insider trades from CRA INTERNATIONAL, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
CRA International reported Q2 revenue up 12.8% YoY, beating estimates. Stock rose 5.1% but market reaction was muted. Company expanded credit facilities to $400M. Analysts project $890.9M revenue by 2029, a 43% upside. Concerns include debt levels and earnings volatility.
2 min readSimply Wall St discusses CRA International (CRAI) after it refinanced and expanded its credit facility to US$400 million in Aug 2026. The article cites record Q2 revenue of US$210.82 million, net income of US$13.51 million, ongoing share repurchases, and a quarterly dividend of US$0.57 per share, and links the move to capital allocation and investment risk.
6 min readCRA International (CRAI) reported Q2 FY2026 revenue of $210.8 million, up 12.8%, and non-GAAP EPS of $2.16, up 14.9%. Non-GAAP EBITDA was $26.8 million. Management raised full-year 2026 revenue guidance to $805-$820 million and reaffirmed EBITDA margin of 12.0%-13.0%. The company repurchased shares and expanded its $400 million credit facility.
6 min readCharles River Associates (CRAI) shares rose about 20% over three months. In Q2, revenue grew 12.8% to $210.8 million, with gains across most practices. Management raised fiscal 2026 constant-currency revenue guidance to $805-$820 million and kept a 12%-13% non-GAAP EBITDA margin outlook, while higher costs and working-capital pressure affect cash conversion.
6 min readCRA International (CRAI) reported Q2 revenue up 12.8% year over year to $210.8 million, with Management Consulting up 25.5% and international up 32.9%. Management raised fiscal 2026 constant-currency revenue guidance to $805-$820 million. Costs and cash use remain concerns, with non-GAAP EBITDA margin down to 12.1% and net debt of $197.6 million.
6 min readCRA International reported Q2 2026 record quarterly revenue, up 12.8% year over year, with 95% of its portfolio contributing. Full-year 2026 revenue guidance was raised to $805 million to $820 million, with non-GAAP EBITDA margin of 12.0% to 13.0%. The company expanded its $400 million credit facility and returned $31.4 million to shareholders.
6 min readCRA International (NASDAQ:CRAI) reported Q2 CY2026 revenue of $210.8 million, up 12.8% year over year, exceeding Wall Street’s revenue estimate by 6%, according to the company and analysts. Non-GAAP adjusted EPS was $2.16, up from $1.88 a year earlier and 0.6% above consensus. The stock rose 1.9% to $179.96 after results.
4 min readCRA INTERNATIONAL, INC. (CRAI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contacts: Eric Nierenberg Nicholas Manganaro Charles River Associates Sharon Merrill Advisors investor@crai.com crai@investorrelations.com 617-425-3020 617-542-5300 CHARLES RIVER ASSOCIATES (CRA) REPORTS FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2026 Record Revenue
4 min readCRA INTERNATIONAL, INC. (CRAI) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001053706 0001053706 2026-07-16 2026-07-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report
2 min readBriaCell Therapeutics (Nasdaq: BCTX, BCTXL; TSX: BCT) said it hired Charles River Associates (CRA) and Kaleio to support commercial strategy, market-access evaluation, and brand planning for Bria-IMT. Bria-IMT is in an ongoing pivotal Phase 3 study for metastatic breast cancer and is not yet approved.
3 min read
